Iconovo (ICO) - Total Assets
Based on the latest financial reports, Iconovo (ICO) holds total assets worth Skr173.25 Million SEK (≈ $18.64 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Iconovo cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Iconovo - Total Assets Trend (2015–2025)
This chart illustrates how Iconovo's total assets have evolved over time, based on quarterly financial data. See ICO net asset value for net asset value and shareholders' equity analysis.
Iconovo - Asset Composition Analysis
Current Asset Composition (December 2025)
Iconovo's total assets of Skr173.25 Million consist of 9.2% current assets and 90.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 5.0% |
| Accounts Receivable | Skr5.43 Million | 4.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr8.63 Million | 6.6% |
| Intangible Assets | Skr110.46 Million | 84.3% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Iconovo's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Iconovo.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iconovo's current assets represent 9.2% of total assets in 2025, a decrease from 45.8% in 2015.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 44.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 84.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 84.3% of total assets.
Iconovo Competitors by Total Assets
Key competitors of Iconovo based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
Iconovo - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.70 | 1.38 | 5.47 |
| Quick Ratio | 3.70 | 1.38 | 5.40 |
| Cash Ratio | 0.00 | 0.00 | 4.81 |
| Working Capital | Skr35.94 Million | Skr4.51 Million | Skr42.97 Million |
Iconovo - Advanced Valuation Insights
This section examines the relationship between Iconovo's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | Skr131.08 Million |
| Market Capitalization | $9.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Iconovo's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Iconovo's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Iconovo (2015–2025)
The table below shows the annual total assets of Iconovo from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr131.08 Million ≈ $14.11 Million |
-10.02% |
| 2024-12-31 | Skr145.69 Million ≈ $15.68 Million |
+13.75% |
| 2023-12-31 | Skr128.08 Million ≈ $13.78 Million |
+5.62% |
| 2022-12-31 | Skr121.27 Million ≈ $13.05 Million |
-18.36% |
| 2021-12-31 | Skr148.54 Million ≈ $15.99 Million |
+47.01% |
| 2020-12-31 | Skr101.04 Million ≈ $10.87 Million |
-11.17% |
| 2019-12-31 | Skr113.75 Million ≈ $12.24 Million |
+56.47% |
| 2018-12-31 | Skr72.70 Million ≈ $7.82 Million |
+72.70% |
| 2017-12-31 | Skr42.10 Million ≈ $4.53 Million |
+109.37% |
| 2016-12-31 | Skr20.11 Million ≈ $2.16 Million |
+75.35% |
| 2015-12-31 | Skr11.47 Million ≈ $1.23 Million |
-- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more